Enforcement record

先駆け審査指定制度対象品目の募集 disclosure naming ニプロ株式会社

ニプロ株式会社 (Pharmaceutical Affairs Act)

This page records one action from a Japanese government disclosure, including the published name, governing law, authority, action details, and official source.

Pharmaceutical Affairs ActMinistry of Health, Labour and WelfareGovernment disclosure5 October 2017

Action type

先駆け審査指定制度対象品目の募集

Law

Pharmaceutical Affairs Act

Authority

Ministry of Health, Labour and Welfare

Action date

5 October 2017

Current page: Enforcement record

This screen focuses on one disclosed action: the published name, governing law, authority, facts, source status, and review evidence.

Source verification

Public-source and preservation status

Publishing authority
Ministry of Health, Labour and Welfare
Official source URL
Recorded by RegBase
Entity match
Not confirmed; shown under the published name
Kiroku preservation
Queued for preservation
Captured: Jul 12, 2026, 03:35 PM JST

“Confirmed” means that RegBase matched this record to the cited public disclosure or entity under the stated checks. It does not verify the truth of the disclosure or guarantee the entity’s current status, creditworthiness, or any legal conclusion.

Available sources and saved files are listed in the public documents section below.

Public documents and saved materials

View the original publications, see what was preserved, or download each file below.

Loading materials…

Action summary

Company
ニプロ株式会社Japanese only
Original: ニプロ株式会社
Governing law
Pharmaceutical Affairs Act
薬事法
Action type
先駆け審査指定制度対象品目の募集
先駆け審査指定制度対象品目の募集
Action date
5 October 2017
Issuing authority
Ministry of Health, Labour and Welfare
厚生労働省

Violation

Machine-translated summary — verify against original

STR01 (Autologous Bone Marrow Mesenchymal Stem Cells) for improvement of neurological symptoms and functional impairments associated with spinal cord injury

Show original Japanese text

STR01（自家骨髄間葉系幹細胞）脊髄損傷に伴う神経症候や機能障害の改善

Compliance context

Context needed

This is a public Japanese regulatory disclosure. The exact legal effect depends on the cited source and regulator.

Japanese regulatory disclosure under Pharmaceutical Affairs Act.

Review the original Japanese source and determine relevance to your counterparty-risk workflow.

This context is an operational aid for review workflows, not a credit opinion or legal conclusion.

Language

日本語版を見る (Japanese)

About this recordAggregated and translated from public Japanese government disclosures. The English text is for reference only — authoritative content is the linked Japanese source.